Literature DB >> 3004552

Inhalation and injection studies in rats using dust samples from chrysotile asbestos prepared by a wet dispersion process.

J M Davis, J Addison, R E Bolton, K Donaldson, A D Jones.   

Abstract

Long term inhalation studies and intraperitoneal injection studies in rats were undertaken with a series of chrysotile asbestos dusts. Three dust samples were generated from chrysotile modified by the wet dispersion process (WDC) and one was from unmodified chrysotile. Following a 1 year inhalation period, all the chrysotile samples proved extremely fibrogenic and carcinogenic and there were no significant differences between the WDC dusts and normal chrysotile. In all experimental groups approximately 25% of animals developed pulmonary carcinomas and in the oldest rats advanced interstitial fibrosis occupied on average 10% of all lung tissue. In the injection studies all the dust samples produced mesotheliomas in over 90% of animals. Very little chrysotile remained in the lungs of the animals that survived longest following dust inhalation and what there was was present as individual chrysotile fibrils. It is suggested that chrysotile is potentially the most harmful variety of asbestos as shown in these and other animal studies but that it is removed from lung tissue quite rapidly. In the long lived human species this may mean that except where exposure levels are very high and of long duration, chrysotile should be less hazardous than other asbestos types.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3004552      PMCID: PMC2013076     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  9 in total

1.  A microscope eyepiece graticule for the evaluation of fibrous dusts.

Authors:  W H Walton; S T Beckett
Journal:  Ann Occup Hyg       Date:  1977-07

2.  Further observations on the short-term retention and clearance of asbestos by rats, using UICC reference samples.

Authors:  A P Middleton; S T Beckett; J M Davis
Journal:  Ann Occup Hyg       Date:  1979

3.  Variations in the carcinogenicity of mineral fibres.

Authors:  R E Bolton; J M Davis; K Donaldson; A Wright
Journal:  Ann Occup Hyg       Date:  1982

4.  Influence of dose and fiber type on respiratory malignancy risk in asbestos cement manufacturing.

Authors:  H Weill; J Hughes; C Waggenspack
Journal:  Am Rev Respir Dis       Date:  1979-08

5.  Carcinogenicity of fibrous glass: pleural response in the rat in relation to fiber dimension.

Authors:  M F Stanton; M Laynard; A Tegeris; E Miller; M May; E Kent
Journal:  J Natl Cancer Inst       Date:  1977-03       Impact factor: 13.506

6.  Fibre type and concentration in the lungs of workers in an asbestos cement factory.

Authors:  B Gylseth; G Mowé; A Wannag
Journal:  Br J Ind Med       Date:  1983-11

7.  Mass and number of fibres in the pathogenesis of asbestos-related lung disease in rats.

Authors:  J M Davis; S T Beckett; R E Bolton; P Collings; A P Middleton
Journal:  Br J Cancer       Date:  1978-05       Impact factor: 7.640

8.  Mesotheliomata in rats after inoculation with asbestos and other materials.

Authors:  J C Wagner; G Berry; V Timbrell
Journal:  Br J Cancer       Date:  1973-08       Impact factor: 7.640

9.  The effects of the inhalation of asbestos in rats.

Authors:  J C Wagner; G Berry; J W Skidmore; V Timbrell
Journal:  Br J Cancer       Date:  1974-03       Impact factor: 7.640

  9 in total
  3 in total

1.  A commentary on Roggli's "The So-Called Short-Fiber Controversy".

Authors:  David Egilman; Triet Tran
Journal:  Int J Occup Environ Health       Date:  2016-05-24

2.  Effects of electrostatic charge on the pathogenicity of chrysotile asbestos.

Authors:  J M Davis; R E Bolton; A N Douglas; A D Jones; T Smith
Journal:  Br J Ind Med       Date:  1988-05

3.  Significance of durability of mineral fibers for their toxicity and carcinogenic potency in the abdominal cavity of rats in comparison with the low sensitivity of inhalation studies.

Authors:  F Pott; M Roller; K Kamino; B Bellmann
Journal:  Environ Health Perspect       Date:  1994-10       Impact factor: 9.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.